Common Contracts

3 similar Underwriting Agreement contracts by Onconova Therapeutics, Inc.

46,588,234 Shares of Common Stock Pre-Funded Warrants to Purchase 12,235,295 Shares of Common Stock and 58,823,529 Warrants to Purchase 1,470,588.225 Shares of Series B Convertible Preferred Stock Onconova Therapeutics, Inc. UNDERWRITING AGREEMENT
Underwriting Agreement • April 30th, 2018 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • New York

Onconova Therapeutics, Inc. a Delaware corporation (the “Company”), proposes to issue and sell to H.C. Wainwright & Co., LLC (the “Underwriter”) an aggregate of 46,588,234 Units (as defined below) and 12,235,295 Pre-Funded Units (as defined below) representing (i) an aggregate of (a) 46,588,234 shares (the “Firm Shares”) of the common stock, par value $0.01 per share, of the Company (“Common Stock”) and (b) pre-funded warrants to purchase 12,235,295 shares of Common Stock at an exercise price of $0.01 per share (the “Pre-Funded Warrants”); and (ii) 58,823,529 warrants (the “Firm Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”) to purchase an aggregate of 1,470,588.225 shares of the Series B Convertible Preferred Stock, par value $0.01 per share, of the Company (“Series B Preferred Stock”). The amount and form of the Firm Securities to be purchased by the Underwriter is set forth opposite its name on Schedule I hereto. The Company also

AutoNDA by SimpleDocs
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!